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Abstract 
A series of novel amidinourea derivatives was synthesized, and the compounds were evaluated as 
inhibitors of MDA-MB-231 human breast cancer cell proliferation. In addition, a second series of 
triazine derivatives designed as rigid congeners of the amidinoureas was synthesized, and the 
compounds were evaluated for their antiproliferative activity. Among the two series, amidinourea 
3d (N-[N-[8-[[N-(morpholine-4-carbonyl)carbamimidoyl] amino]octyl]carbamimidoyl]morpholine-4-
carboxamide) emerged as a potent anticancer hit compound with an IC50 value of 0.76 mm, similar 
to that of tamoxifen 
 
TEXT 
Breast cancers are solid tumors which result from a series of non-random molecular alterations, 
transforming normal cells into cancer cells with invasive and metastatic potential. However, the 
steps of tumor progression are not yet well elucidated in breast cancer.1 Breast cancer represents 
today the most common malignant tumor and the second most lethal cancer among women 
preceded only by lung cancer.2-3 Women have a 1 in 8 lifetime risk of developing breast cancer and 1 
in 35 risk of breast cancer causing death in the US and Europe. Several studies have established that 
estrogens are predominantly involved in the initiation and proliferation of breast cancer and much 
efforts are now being devoted to block estrogen formation and action.4 Most common breast cancer 
therapies are based on the use of drugs that stop estrogen and progesterone from helping breast 
cancer cells grow.5 These drugs include the natural drug paclitaxel,6 aromatase inhbitors7 such as the 
triazole letrezole and the estrogen receptor modulators tamoxifen and raloxifen.8 (Figure 1). 
However, there is constant of need to find novel anticancer molecules with improved activity, 
selctivity and reduced side effects. 
Amidinoureas represent an interesting and underexplored class of compounds.9-10 We recently 
discovered both macrocyclic and linear amidinurea derivatives endowed with antifungal11 and 
antiviral activity.12 Some amidinurea derivatives also showed anti-proliferative properties13 probably 
due to their ability to mimicking the natural nucleobases and thus to interact with DNA. 
Here, as an extension of our previous work, we describe the design and synthesis of two series of 
mono and bis-amidinourea derivatives and the evaluation of their anti-proliferative activity against 
MDA-MB-231 human breast cancer cells. In addition, a series of triazine analogues of amidinureas 
were designed. In fact, triazines with the general structure A represent the rigid analogues of C as 
shown in Figure 1. Triazines have been shown to possess antitumoral properties,14 but their activity 
on breast cancer cells has not yet been fully investigated.15 
  
Figure 1. Common drugs active on breast cancer cells. General structures of amidinoureas and 
triazines 
 
We first focused on the synthesis of amidinureas with general structures A and B. Scheme 1. The 
thiopseudourea 1 was reacted with 1,8-diaminooctane affording the biguanide 2. The latter was 
then treated with different primary and secondary amines in refluxing THF affording the desired Boc-
protected bis-amidinoureas which were in turn converted into the desired products 3a-f upon 
treatment with freshly prepared HCl/AcOEt. Similarly, treatment of 1 with benzylamine or p-Cl-
aniline led to guanidines 4a-b, which were reacted with appropriate amines leading, after Boc group 
cleavage, to the desired amidinureas 5a-e.12 
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Scheme 1. Synthesis of amidinourea substrates 
The triazine analogues were synthesised as described in Scheme 2. Cyanuric chloride 6 was first 
reacted with different amines/anilines affording the derivatives 7a-c. These latter were then reacted 
with a series of piperazines leading to the final products 8a-g. A bis-triazine 9 was also synthesised 
by reacting 6 with p-xylylenediamine. Compound 9 was further functionalised through reaction with 
benzylamine leading to derivative 10. 
 
 
i. Amine, DCE, -40 oC, 3h. ii. Piperazine-R1, DCE, 80 oC, MW, 
20 min. iii. p-xylylenediamine, DCE, -40 oC, 3h. iv. 
Benzylamine, DCE, 80 oC, MW, 20 min. 
Cmpd R R1 
8a 4-Cl-Ph Ph 
8b Bn Ph 
8c PhCH2CH2 Ph 
8d Bn Boc 
8e Bn 
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All the compounds were then evaluated for their anti-proliferative effects on MDA-MB-231 human 
breast cancer cells. The inhibition of proliferation was monitored after 30 and 60 hours as shown in 
Figure 2 and Figure 3 (for compound 3d). A number of compounds were shown to inhibit cellular 
proliferation at 50-100 M. The triazines, with the exception of 8a and 8e proved to be inactive, 
whilst most of the bis-amidinurea showed a good activity profile. In particular 3b produced a cell 
proliferation inhibition of 80% when used at 1-10M. Among compounds 3, the derivative 3b 
bearing a Cl-phenyl moiety on the amidinurea group proved to be the most promising compound in 
term of inhibition of cell proliferation. The replacement of the aryl moiety with a benzyl (3a), or an 
heterocycle (morpholine in 3d, pyrrolidine in 3e, pyrroline in 3f) led to derivatives still able to inhibit 
the cell proliferation but at higher dose than 3b. Interestingly, compound 3c bearing a longerside 
chain did not show any activity against MDA-MB-231 cells. The compounds 5a-e also proved to be 
not active, thus accounting for the importance of a long aliphatic backbone for the anticancer 
activity. Similarly, the triazine analogues of compounds 5 also showed poor inhibition of MDA-MB-
231 cells cell proliferation. However, at higher concentrations (50-100 M) the derivatives 7c and 8a 
proved to be able to inhibit the growth of MDA-MB-231 cells at >80%. 
 
 
 Figure 2. Anti-proliferative activity of amidinourea and triazine derivatives on MDA-MB-231 human 
breast cancer cells 
 
Figure 3. Effect of 3d on MDA-MB-231 cell growth. The effect of compound 3d on the proliferation 
of MDA-MB-231 is shown in Figure 3. The cells were incubated for 24 hours prior the addition of 3d 
(point A) at 0, 1, 10, 50 100 M. The cell growth was evaluated after 30h (point B) and 60h (point C) 
in the presence of 3d. 
 
The inhibitory efficiency for some of the most active compounds was then evaluated against the 
breast cancer cell line MDA-MB-231. The IC50 values are summarised in Table 1 and were compared 
with the data reported for tamoxifen.16 The three amidinureas 3d-f confirmed the data previously 
observed emerging as potent breast cancer inhibitors. In particular compound 3d, bearing a 
morpholine substituent on the amidinurea moiety showed  IC50 = 0.76 M, close to that of 
tamoxifen, thus proving to be a valuable candidate for further development. Also the derivatives 3e 
and 3f showed a good activity with IC50 values of 1.3 and 1.5 respectively, as well as the aryl 
amidinurea 3b which showed an IC50 = 4.9M. Again, the triazine derivatives 8a and 8e and the 
amidinurea 5e showed poor inhibition with IC50 values >12M.  
 
Table 1. 
 Compounds 
3a 3b 3d 3e 3f 5e 8a 8e Tamoxifen 
IC50 (M) 
MDA-MB-231 
67.5 4.9 0.76 1.3 1.5 22.1 12 74.7 0.6616 
 
In conclusion, this work showed the potentiality of amidinourea compounds as potential anticancer 
agent, leading to the identification of a new promising hit candidate compounds 3d. Currently 
additional derivatives are under investigation in our lab. 
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General Methods 
Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker 400 MHz spectrometer. 1H 
and 13C spectra were referenced relative to the solvent residual peaks and chemical shifts (δ) 
reported in ppm downfield of trimethylsilane (CDCl3 δ H: 7.26 ppm, δ C: 77.0 ppm). Coupling 
constants (J) are reported in Hertz. Splitting patterns are abbreviated as follows: singlet (s), doublet 
(d), triplet (t), quartet (q), multiplet (m), broad (br) or some combination of these.  Thin layer 
chromatography (TLC) was performed using commercially available pre-coated plates and visualized 
with UV light at 254 nm. Permanganate or nhynidrine were used to reveal the products. Flash 
column chromatography was carried out using Silica 60 Å. 
Compounds 5a-e were synthesised as previously reported. Magri, A.; Reilly, R. Scalacci, N.; Radi, M.; 
Hunter, M.; Ripoll, M.; Patel, A.; Castagnolo, D. Bioorg. Med. Chem. Lett. 2015, 25, 5372-5376. 
 
Synthesis of biguanide 2 
 
 
Diamine (1 g, 6.93 mmol, 1.1 eq) and 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (3.67 
g, 12.65 mmol, 2 eq) were mixed in CH2CL2 (10 mL)  and the mixture was stirred at r.t. for 12 h. The 
reaction mixture was then quenched with water and extracted with ethyl acetate (3 x 50 mL). The 
combined organic phase was concentrated under reduced pressure. Yellow oil was obtained. 
1H NMR (400 MHz CDCl3) δ 11.48 (br, 1H), 8.11 (br, 1H), 3.37 (m, 2H), 1.49 (s, 9H), 1.47 (s, 9H), 1.50-
1.20 (br, 6H) ppm.  
 
General procedure for the synthesis of compounds 3a-g 
Guanidine 2 (400 mg, 0.63 mmol, 1eq) was dissolved in THF (5 mL). The apropriate amine was then 
added (2eq) and the mixture was stirred overnight at reflux. The reaction mixture was washed with 
cold water and extracted with ethyl acetate (3x20 mL). The crude product was purified by column 
chromatography using AcOEt/Hexane 1:4 as eluent affording the Boc-protected compound. This 
latter was dissolved in AcOEt (1 mL) and then treated with freshly prepared HCl/AcOEt (3 mL). The 
mixture was stirred for 24h. The solvent was removed affording the desired amidinourea 3. 
 
 
 
 
Yield: 61% 1H NMR (400 MHz MeOD-d6) 7.29-7.28 (m, 5H), 4.34 (s, 2H), 3.25-3.27 (m, 2H), 1.62, (m, 
2H), 1.24 (m, 4H) ppm. 13C NMR (100 MHz MeOD-d6) δ 154.3, 154.0, 138.1, 128.3, 127.2, 127.1,  
43.1, 41.2, 28.6, 27.9, 26.18 ppm. 
 
 
Yield: 42% 1H NMR (400 MHz MeOD-d6) 7.44 (d, 2H, J = 8 Hz), 7.36 (d, 2H, J = 8 Hz), 3.22 (m, 2H), 
1.49, (m, 2H), 1.26 (m, 4H) ppm. 13C NMR (100 MHz MeOD-d6) δ 153.4, 151.9, 137.1, 129.4, 128.0, 
121.6, 41.5, 29.0, 28.3, 26.4  ppm. 
 
 
 Yield: 53% 1H NMR (400 MHz MeOD-d6) 7.27-7.14 (m, 5H), 3.40 (m, 2H), 3.24 (m, 2H), 2.79 (m, 2H), 
1.60, (m, 2H), 1.25 (m, 4H) ppm. 13C NMR (100 MHz MeOD-d6) δ 154.8, 154.5, 139.4, 129.1, 128.9, 
126.8, 41.8, 41.6, 35.8, 29.3, 28.5, 26.8 ppm. 
 
 
Yield: 40% 1H NMR (400 MHz MeOD-d6) 3.66 (m, 4H), 3.52 (m, 4H), 3.28 (m, 2H), 1.63 (m, 2H), 1.28 
(m, 4H) ppm. . 13C NMR (100 MHz MeOD-d6) δ 155.0, 153.2, 66.1, 44.4, 41.4, 28.8, 28.0, 26.4 ppm. 
 
 
Yield: 56% 1H NMR (400 MHz MeOD-d6) 3.47-3.42 (m, 4H), 3.29-3.26 (m, 2H), 2.01 (m, 2H), 1.89 (m, 
2H), 1.64 (m, 2H), 1.39 (m, 4H) ppm. 13C NMR (100 MHz MeOD-d6) δ 155.4, 152.9, 46.9, 46.6, 41.8, 
29.3, 28.5, 26.8, 26.2, 24.7 ppm. 
 
 
Yield: 55% 1H NMR (400 MHz DMSO-d6) 5.89 (s, 2H), 4.26 (m, 2H), 4.09 (m, 2H), 3.21 (m, 2H), 1.48 
(m, 2H), 1.26 (m, 4H) ppm. 13C NMR (100 MHz DMSO-d6) δ 154.8, 152.2, 125.9, 125.7, 53.9, 53.8, 
47.2, 28.9 ,28.3, 26.0 ppm. 
 
 
General procedure for the synthesis of triazines 7. 
Cyanuric chloride (2.7 mmol) was dissolved in 30 mL of DCE and the mixture was cooled at -40 oC. 
The appropriate amine/aniline (2.7 mmol) was added and the mixture was stirred at the same 
temperature for 3h. The mixture was quenched with water. The organic phase was then washed 
twice with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The crude 
product was used in the next step without any further purification. 
 
Yield: 64% 1H NMR (400 MHz CDCl3) 7.60 (br s, 1H), 7.48 (d, 2H, J = 8 Hz), 7.35 (d, 2H, J = 8 Hz) ppm.  
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Yield: 64% 1H NMR (400 MHz CDCl3) 7.36-7.24 (m, 5H), 6.67 (br s, 1H), 4.66 (d, 2H, J = 7.8 Hz) ppm.  
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Yield: 57% 1H NMR (400 MHz CDCl3) 7.30-7.16 (m, 5H), 6.63 (br s, 1H), 3.75 (m, 2H), 2.89 (t, 2H, J = 
7.4 Hz) ppm. 
 
Yield: 64% 1H NMR (400 MHz CDCl3) 7.23 (s, 2H), 4.46 (s, 2H) ppm. 
 Genaral procedure for the synthesis of triazines 8 
The appropriate triazine 7 (1 mmol) was dissolved in 2 mL of DCE in a microwave vial. The 
appropriate piperazine (1 mmol) was added and the reaction mixture was heated at 80 oC under 
microwave irradiation for 20 minutes (2 x 10 minutes runs). The mixture was diluted with brine (10 
mL) and extracted with AcOEt (5 mL). The combined organic phases were dried over MgSO4, filtered 
and concentrated under reduced pressure. The crude product was purified by chromatography on 
silica gel, using hexane/EtOAc (10:1) as eluent. 
 
 
Yield: 82% 1H NMR (400 MHz CDCl3) 7.47 (d, 2H, J = 8 Hz), 7.32-7.27 (m, 4H), 6.96-6.91 (m, 3H),  
4.01-3.96 (m, 4H), 3.23-3.22 (m, 4H) ppm. 13C NMR (100 MHz MeOD-d6) δ 162.1, 161.1, 154.5, 
137.2, 136.6, 128.7, 128.6, 127.8, 127.7, 127.6, 127.0, 44.5, 42.1 ppm. 
 
 
Yield: 76% 1H NMR (400 MHz CDCl3) 7.33-7.21 (m, 7H), 6.94-6.90 (m, 3H), 5.98 (brs, 1H), 4.61 (d, 2H, 
J = 4Hz), 3.95 (m, 4H), 3.17 (m, 4H) ppm. 13C NMR (100 MHz MeOD-d6) δ 169.1, 165.6, 164.4, 138.1, 
129.3, 128.7, 128.6, 127.8, 127.5, 127.3, 116.8, 49.6, 44.9, 43.3 ppm. 
 
 
 
Yield: 67% 1H NMR (400 MHz CDCl3) 7.30-7.24 (m, 7H), 6.96-6.89 (m, 3H), 5.55 (brs, 1H), 3.97 (m, 
4H), 3.67 (M, 2H), 3.21 (m, 4H), 2.88 (m, 2H) ppm. 
 
Yield: 87% 1H NMR (400 MHz CDCl3) 7.31-7.25 (m, 5H), 4.57 (s, 2H), 3.76 (m, 4H), 3.44 (m, 4H), 1.45 
(s, 9H) ppm. 13C NMR (100 MHz MeOD-d6) δ 174.9, 167.5, 161.1, 154.5, 138.8, 128.7, 127.5, 127.4, 
80.5, 44.7, 43.8, 43.4, 28.3 ppm. 
 
 
Yield: 64% 1H NMR (400 MHz CDCl3) 8.32 (d, 2H, J = 4Hz), 7.32-7.28 (m, 5H), 6.52 (t, 1H, J = 4Hz), 
5.90 (br s, 1H), 4.60 (s, 2H), 3.84 (br m, 8H) ppm. 13C NMR (100 MHz MeOD-d6) δ 178.8, 169.1, 
165.6, 161.5, 157.8, 138.1, 128.6, 127.5, 127.4, 110.3, 45.0, 43.3, 43.2 ppm. 
 
 
Yield: 64% 1H NMR (400 MHz CDCl3) 8.16 (s, 1H), 7.30-7.23 (m, 5H), 6.51 (s, 1H), 4.57 (s, 2H), 3.81 (br 
m, 8H) ppm. 13C NMR (100 MHz MeOD-d6) δ 189.1, 178.9, 169.9, 167.0, 158.9, 158.5, 152.3, 134.3, 
128.6, 127.5, 110.6,  44.9, 43.4, 43.2,  ppm. 
 
 
Yield: 64% 1H NMR (400 MHz CDCl3) 8.57 (d, 2H, J = 3.4Hz), 7.66 (m, 1H), 7.41 (m, 1H), 7.31-7.26 (m, 
5H), 7.20 (m, 1H), 5.71 (br s, 1H), 4.56 (s, 2H), 3.84 (m, 4H), 3.68 (s, 2H), 2.52 (m, 4H) ppm. 
 
 
Yield: 64% 1H NMR (400 MHz CDCl3) 7.30-7.14 (m, 7H), 4.48 (s, 2H), 4.26 (s, 2H) ppm. 13C NMR (100 
MHz MeOD-d6) δ 164.4, 163.7, 150.9, 136.3, 129.3, 128.9, 121.7, 120.6, 116.7, 49.2, 43.6 ppm. 
Cell proliferation screening and IC50 determination 
The MDA-MB-231 cell line was obtained from ATCC and cultured in DMEM, supplemented with 10% 
(v/v) foetal calf serum (FCS) and penicillin/streptomycin. Cell identity was authenticated by short 
tandem repeat profiling (DDC, DNA Diagnostics Centre, London, UK). All cell culture reagents were 
from ThermoFisher Scientific (Paisley, UK). 
For all compound testing MDA-MB-231 cells were incubated in media containing only 0.5% FCS for 
24 hours prior the start of an experiment to synchronise proliferation. The effect of the synthesised 
compounds on cell proliferation was determined using an xCELLigence DP real time cell analyser 
according to the manufacturer’s instructions (Acea Biosciences Inc., CA, USA) and as previously 
reported17. Cells were seeded onto an xCELLigence E plate at 20,000 cells/well, in normal growth 
media for 24 hours prior to the addition of compound or DMSO only as control. Measurements were 
taken every 15 minutes for up to 100 h to determine cell proliferation.  
To determine IC50 MDA-MB-231 were put in a 96-well plate at 5000 cell/well and incubated for 24 
hours in the presence of titrated compound.  To quantify cell proliferation, WST-1 (Sigma-Aldrich, 
Dorset, UK) was added to each well and cells were incubated at 37°C for 4 hours to allow colour 
change to develop. Absorbance at 490nm was measured using a FLUOstar Omega plate reader. IC50 
analysis was performed by Origin Software (Silverdale Scientific, Buckinghamshire, UK) 
